GEN Exclusives

More »

GEN News Highlights

Back to Item »

Meda Outlicenses Elidel and Xerese to Valeant for $76M Up Front

Deal will bring Meda another estimated $130 million over next 18 months and royalties of at least $120 million between 2013 and 2015.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?